HAP and VAP clinical practice guidelines by Infectious Diseases Society of America-What′s new?

doi:10.3877/cma.j.issn.2096-1537.2016.04.007

Abstract

Abstract:

Hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) remain the most frequent nosocomial infection in critical ill patients and bring about higher hospitalization cost, longer length of stay in hospital and increased mortality. In 2016, with advances in evidence-based guideline methodology and analysis of new studies related to the diagnosis and treatment of HAP and VAP, Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) have collaborated to create updated guidelines for the diagnosis and treatment of HAP and VAP based on last HAP/VAP guidelines published in 2005. Here, we will make a brief introduction of important updates of these new guidelines.

Key words: Hospital acquired pneumonia, Ventilator-associated pneumonia, Guidelines

Yongbo Huang, Yimin Li. HAP and VAP clinical practice guidelines by Infectious Diseases Society of America-What′s new?[J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2016, 02(04): 258-262.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://icu.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-1537.2016.04.007

https://icu.cma-cmc.com.cn/EN/Y2016/V02/I04/258

References 19

[1]	Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society[J]. Clin Infect Dis, 2016, 63(5): e61-e111.
[2]	Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia[J]. Antimicrob Agents Chemother, 2014, 58(9): 5262-5268.
[3]	Chalmers JD, Rother C, Salih W, et al. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis[J]. Clin Infect Dis, 2014, 58(3): 330-339.
[4]	Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies[J]. Lancet Infect Dis, 2013, 13(8): 665-671.
[5]	Giantsou E, Liratzopoulos N, Efraimidou E, et al. Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria[J]. Intensive Care Med, 2005, 31(11): 1488-1494.
[6]	Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis[J]. Clin Infect Dis, 2012, 55(5): 651-662.
[7]	Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections[J]. Evid Based Child Health, 2013, 8(4): 1297-1381.
[8]	Nseir S, Favory R, Jozefowicz E, et al. Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study[J]. Crit Care, 2008, 12(3): R62.
[9]	Martin-Loeches I, Povoa P, Rodriguez A, et al. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study[J]. Lancet Respir Med, 2015, 3(11): 859-868.
[10]	Rello J, Sa-Borges M, Correa H, et al. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices[J]. Am J Respir Crit Care Med, 1999, 160(2): 608-613.
[11]	Namias N, Samiian L, Nino D, et al. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies[J]. J Trauma, 2000, 49(4): 638-645.
[12]	Tsai D, Lipman J, Roberts JA. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill[J]. Curr Opin Crit Care, 2015, 21(5): 412-420.
[13]	Chuang Y C, Cheng C Y, Sheng W H, et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis[J]. BMC Infect Dis, 2014, 14(1): 102.
[14]	Montravers P, Dupont H, Bedos JP, et al. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting[J]. Intensive Care Med, 2014, 40(7): 988-997.
[15]	Chaari A, Pham T, Mnif B, et al. Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study[J]. Intensive Care Med, 2015, 41(11): 2018-2019.
[16]	Burkhardt O, Rauch K, Kaever V, et al. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint[J]. Int J Antimicrob Agents, 2009, 34(1): 101-102.
[17]	Dimopoulos G, Poulakou G, Pneumatikos I A, et al. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis[J]. Chest, 2013, 144(6): 1759-1767.
[18]	Pugh R, Grant C, Cooke R P, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults[J]. Cochrane Database Syst Rev, 2015, 8(8): CD007577.
[19]	Leone M, Bechis C, Baumstarck K, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial[J]. Intensive Care Med, 2014, 40(10): 1399-1408.

Please choose a citation manager

Content to export